| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Lucatumumab Basic information |
| Product Name: | Lucatumumab | | Synonyms: | Lucatumumab;Research Grade Lucatumumab(DHD68905);Research Grade Lucatumumab;Lucatumumab (anti-CD40) | | CAS: | 903512-50-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lucatumumab Structure]() |
| | Lucatumumab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Lucatumumab Usage And Synthesis |
| Uses | Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research[1][2]. | | IC 50 | CD40 | | References | [1] Luqman M, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008 Aug 1;112(3):711-20. DOI:10.1182/blood-2007-04-084756
[2] Drgona L, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94. DOI:10.1016/j.cmi.2018.03.022 |
| | Lucatumumab Preparation Products And Raw materials |
|